Posted on March 4, 2016
Sentri7 was recently named the market-leading Clinical Decision Support Surveillance solution by KLAS. Sentri7 had the highest scores for overall product satisfaction and product quality and was awarded top honors for exceptional:
Of surveyed participants, 85% rated moderate to significant impact on clinical outcomes and 92% would buy Sentri7 again.
Customers specifically called out three distinct advantages to Sentri7:
Significantly Impacts Outcomes and Patient Care
Customers state Sentri7 has a moderate to significant impact on clinical outcomes including decreased length of stay, antibiotic usage, medication costs and adverse reactions.
Highly Customizable and Easy to Use
An easily customizable, robust and flexible system Sentri7 requires little user training and minimal IT involvement.
KLAS interviewed EMR customers on current EMR-based surveillance. Allscripts, Cerner and Epic customers reported having few prebuilt rules and a very intensive customization process requiring IT resources and extensive training.
Sentri7 customers shared their sentiments:
“Sentri7 has the flexibility to pull all the clinical data we need to make day-to-day decisions about patients.”
“The customization is what we have found to be the most beneficial to our team. It definitely helps our workflow and helps us achieve more with the time we are given.”
“Sentri7 is an excellent system. It is flexible, and we can tweak it according to our needs. We don’t have to wait for somebody to write our rules for us because we can make our own rules.”
President & CEO of Clinical Software Solutions at Wolters Kluwer, David A. Del Toro, added, “We are honored to have our customers once again acknowledge through KLAS the role Sentri7 plays in helping them achieve these objectives.”
To learn more about how Sentri7 can help you elevate care delivery, lower costs, and save lives, request a product demonstration.
Commentary above collected about Sentri7 by KLAS in March 2015-October 2015 respectively @KLAS Enterprises, LLC. All rights reserved. To see a complete view visit www.KLASResearch.com.